title: Emerging treatments for pemphigoid diseases.
abstract: Incidence of bullous pemphigoid (BP), the main pemphigoid disease, has increased over the past decades. Despite growing insights into pathogenic mechanisms, treatment is still based on systemic immunosuppression. Furthermore, overall mortality is significantly increased, which can be at least partially attributed to immunosuppressive therapy. Other pemphigoid diseases are also still difficult to treat. Hence, there is a so far unmet need for novel treatment options in patients with pemphigoid disease. Based on recent advances in understanding pathogenesis, several novel potential therapeutic targets have emerged. Interestingly, for some of these targets, lead compounds have been developed. Here, we review emerging therapeutic targets for pemphigoid diseases and discuss which compounds are likely be used in the future.
authors.affiliation: Department of Dermatology, University of Lübeck, Lübeck, Germany. ralf.ludwig@uksh.de
authors.forename: Ralf J
authors.initials: RJ
authors.lastname: Ludwig
authors.forename: Kathrin
authors.initials: K
authors.lastname: Kalies
authors.forename: Jörg
authors.initials: J
authors.lastname: Köhl
authors.forename: Detlef
authors.initials: D
authors.lastname: Zillikens
authors.forename: Enno
authors.initials: E
authors.lastname: Schmidt
mesh_terms: D000818:Animals; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods*; D010391:Pemphigoid, Bullous / Q000276:immunology / Q000628:therapy*
keywords: Fcγ receptor; IgE; autoimmune skin blistering; autoimmunity; cytokine; skin; treatment